Safety: what we know, what we dont What clinical trial safety reviews suggest The clinical safety review literature reports several reassuring signals: No meaningful increase in IGF-1 in monitored long-term studies (jofem.org) No clear negative effect on carbohydrate metabolism in testing described (contrast with full hGH) (jofem.org) No clear immunogenicity signal (e.g., anti-AOD antibodies) in the subset assessed in those trials (jofem.org) The major limitation: long-term real-world certainty is thin The problem with many peptides is not that everything is dangerousits that the certainty level is often lower than patients assume
Maintenance and prevention protocol Lower-dose combination approaches support ongoing tissue health and injury prevention in active individuals with chronic tissue demands
Currently pursuing her Masters in Dietetics, Katie is committed to staying at the forefront of science-backed support
Serving all of Orange County Newport Beach, Irvine, Costa Mesa, Anaheim, Fountain Valley
It is critical to recall that all of this data comes from preclinical models (rodent, porcine, in vitro) and limited case studies
swelling of the lips, tongue, or face
